1. Search Result
Search Result
Isoforms Recommended: Bcl-2
Results for "

Bcl‐2

" in MedChemExpress (MCE) Product Catalog:

385

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

13

Peptides

1

Inhibitory Antibodies

72

Natural
Products

18

Recombinant Proteins

9

Isotope-Labeled Compounds

40

Antibodies

36

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125876
    PROTAC Bcl2 degrader-1
    1 Publications Verification

    PROTACs Bcl-2 Family Cancer
    PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1 (Blue: CRBN ligand, Black: linker;Pink: Mcl-1/Bcl-2 inhibitor, Nap-1).
    PROTAC Bcl2 degrader-1
  • HY-135273

    BCL2-IN-1

    Bcl-2 Family Cancer
    A-1211212 (BCL2-IN-1), a chemical probe, is a potent Bcl-2 inhibitor. BCL2-IN-1 binds Bcl-2 with a Ki of <0.01 nM .
    A-1211212
  • HY-RS01417

    Small Interfering RNA (siRNA) Bcl-2 Family Others

    BCL2 Rat Pre-designed siRNA Set A contains three designed siRNAs for BCL2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BCL2 Rat Pre-designed siRNA Set A
    BCL2 Rat Pre-designed siRNA Set A
  • HY-RS01415

    Small Interfering RNA (siRNA) Bcl-2 Family Others

    BCL2 Human Pre-designed siRNA Set A contains three designed siRNAs for BCL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BCL2 Human Pre-designed siRNA Set A
    BCL2 Human Pre-designed siRNA Set A
  • HY-RS01416

    Small Interfering RNA (siRNA) Bcl-2 Family Others

    Bcl2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bcl2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bcl2 Mouse Pre-designed siRNA Set A
    Bcl2 Mouse Pre-designed siRNA Set A
  • HY-143873

    Bcl-2 Family Cancer
    Bcl-2-IN-5 is a BCL-2 inhibitor with IC50s of 0.12 nM, 0.14 nM and 0.22 nM for Bcl-2 wild type, Bcl-2 D103Y and Bcl-2 G101V, respectively. Bcl-2-IN-5 inhibits the cell growth with IC50 values of 0.2 nM and 0.44 nM for Bcl 2-G101V knock-in RS4; 11 and RS4; 11 cells, respectively (WO2021208963A1; Example 155) .
    Bcl-2-IN-5
  • HY-131247

    Bcl-2 Family Inflammation/Immunology Cancer
    Bcl-2-IN-2 is a potent and selective Bcl-2 inhibitor with an IC50 of 0.034 nM and also inhibits Bcl-xL with an IC50 of 43 nM, showing >1000-fold selectivity for Bcl-2 over Bcl-xL .
    Bcl-2-IN-2
  • HY-149009

    Bcl-2 Family Apoptosis Cancer
    Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells .
    Bcl-2-IN-9
  • HY-163309

    Bcl-2 Family Cancer
    Bcl-2-IN-19 (compound 27) is a potent Bcl-2 inhibitor for targeting breast cancer .
    Bcl-2-IN-19
  • HY-136714

    Bcl-2 Family Cancer
    Bcl-2-IN-3 (Compound 10) is a Bcl-2 inhibitor. Bcl-2-IN-3 can be used for the research of cancer .
    Bcl-2-IN-3
  • HY-149623

    Bcl-2 Family Cancer
    Bcl-2-IN-13 is a Bcl-2 inhibitor with an IC50 value of 17 nM. Bcl-2-IN-13 can be used in cancer research .
    Bcl-2-IN-13
  • HY-169083

    Apoptosis Bcl-2 Family Cancer
    Bcl-2-IN-22 (compound 1) is a gold(I) NHC complex with anticancer activity. Bcl-2-IN-22 induces apoptosis via the mitochondrial pathway with an IC50 value of 0.014 μM. In addition, Bcl-2-IN-22 targets BCL-2 family members and exhibits pro-apoptosis and resensitization properties in multidrug-resistant leukemia cells that overexpress BCL-2 .
    Bcl-2-IN-22
  • HY-149622

    Bcl-2 Family Cancer
    Bcl-2-IN-12 (Compound 1) is a Bcl-2 inhibitor (IC50: 6 nM). Bcl-2-IN-12 can be used for cancer research .
    Bcl-2-IN-12
  • HY-149624

    Bcl-2 Family Cancer
    Bcl-2-IN-14 (Compound 13c) is a BCL-2 inhibitor with an IC50 value of 0.471 μM. Bcl-2-IN-14 can be used in cancer research .
    Bcl-2-IN-14
  • HY-149625

    Bcl-2 Family Cancer
    Bcl-2-IN-15 (Compound 13d)) is a Bcl-2 inhibitor (IC50: 363 nM). Bcl-2-IN-15 inhibits the proliferation ofNCI leukemia cancer cell line .
    Bcl-2-IN-15
  • HY-149436

    CDK Cancer
    CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC50=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .
    CDK2/Bcl2-IN-1
  • HY-160108

    Bcl-2 Family Others
    Bcl-2-IN-17 is a Bcl2 inhibitor and can be used for the research of diseases associated with Bcl anti-apoptotic protein .
    Bcl-2-IN-17
  • HY-153953

    Bcl-2 Family Cancer
    Bcl-2-IN-11 (compound 6) is a potent and selective Bcl-2 activity inhibitor, with an IC50 of 0.9 nM. Bcl-2-IN-11 shows weak inhibition of Bcl-xl (IC50 > 1000 nM). Bcl-2-IN-11 can be used for the research of a variety of cancers caused by abnormal overexpression of Bcl-2 family proteins: especially malignant hematologic diseases of acute lymphoid leukemia, etc. Bcl-2-IN-11 can also avoid toxic side effects caused by Bcl-xl inhibition, such as thrombocytopenia .
    Bcl-2-IN-11
  • HY-163308

    Bcl-2 Family Cancer
    Bcl-2-IN-18 (Compound 23) is a breast cancer Bcl-2 inhibitor with a IC50 value of 4.7 μM for MCF-7. Bcl-2-IN-18 has antitumor activity .
    Bcl-2-IN-18
  • HY-162820

    Bcl-2 Family Cancer
    Bcl-2-IN-21 (compound C1) is an iridium compound with anticancer activity that targets and inhibits Bcl-2. Bcl-2-IN-21 inhibits colony formation of cancer cells and induces elevated levels of Bax and caspase 3 .
    Bcl-2-IN-21
  • HY-144791

    Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-6 (compound 10) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.91, 22.30, 42.29, and 48.00 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-6
  • HY-144792

    Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-7 (compound 6) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.17, 22.64, 45.57, and 51.50 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-7
  • HY-176219

    Bcl-2 Family Apoptosis Necroptosis Cancer
    Bcl-2-IN-23 (compound 5) is a selective inhibitor targeting Bcl-2. The IC50 of Bcl-2-IN-23 in HTB-140, HeLa and SW620 cells is 25.7-33.7 μM. Bcl-2-IN-23 can non-covalently competitively bind to Bcl-2 protein, significantly reduce its expression, and induce late apoptosis and necroptosis of cancer cells. Bcl-2-IN-23 enhances the sensitivity of cancer cells to apoptosis and reduces the release of IL-6 inflammatory factors by disrupting the Bcl-2-mediated mitochondrial apoptosis inhibition pathway. Bcl-2-IN-23 can be used for anti-apoptosis research of malignant tumors such as melanoma, cervical cancer, and colorectal cancer .
    Bcl-2-IN-23
  • HY-129702

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-4 (Compound 7) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor .
    MCL-1/BCL-2-IN-4
  • HY-129700

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-2 (Compound 6) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor .
    MCL-1/BCL-2-IN-2
  • HY-174403

    Bcl-2 Family c-Myc Apoptosis Caspase Cancer
    c-MYC/BCL2 ligand 1 iodide is a dual-targeting c-MYC/Bcl-2 G4 ligand with Kd values of 0.90 μM (c-MYC G4) and 0.56 μM (Bcl-2 G4). c-MYC/BCL2 ligand 1 iodide inhibits c-MYC and Bcl-2 gene transcription by binding to G4-forming sequences and downregulates their protein expression. c-MYC/BCL2 ligand 1 iodide inhibits suppresses migration, induces caspase-dependent apoptosis, and triggers cell cycle G1 arrest in MCF-7 cells. c-MYC/BCL2 ligand 1 iodide significantly suppresses tumor growth in a 4T1 syngeneic model with no observable toxicity. c-MYC/BCL2 ligand 1 iodide can be used for the research of breast cancer.
    c-MYC/BCL2 ligand 1 iodide
  • HY-143872

    Bcl-2 Family Cancer
    Bcl-2-IN-4 is a potent, orally active and selective Bcl-2 inhibitor with an IC50 of 1.5 nM. Bcl-2-IN-4 displays >200-fold selectivity over Bcl-xL (IC50 of 411 nM). Bcl-2-IN-4 inhibits RS4; 11 cell proliferation with an IC50 of 2.7 nM (WO2021180040A1; compound 2) .
    Bcl-2-IN-4
  • HY-150540

    Bcl-2 Family Apoptosis Cancer
    Bcl-2-IN-10 is an active Bcl-2 inhibitor that can release up to four nitric oxide (NO) molecules. Bcl-2-IN-10 has cytotoxic activities against cancer cells, such as human leukemia, breast cancer and lung cancer. Bcl-2-IN-10 induces cell apopotosis and arrest cell cycle of G2/M phase, and can be used in cancer-related research .
    Bcl-2-IN-10
  • HY-129701

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-3 (Compound 2) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor with IC50s of 5.95 and 4.78 μM, respectively .
    MCL-1/BCL-2-IN-3
  • HY-144428

    Bcl-2 Family Cancer
    Bcl-2/Mcl-1-IN-2 (compound 2) is a Bcl-2/Mcl-1 inhibitor, with Kis of 0.88 μM and 4.70 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-2 can be used for the research of cancer .
    Bcl-2/Mcl-1-IN-2
  • HY-144430

    Bcl-2 Family Cancer
    Bcl-2/Mcl-1-IN-1 (compound 3) is a Bcl-2/Mcl-1 inhibitor, with Kis of 1.19 μM and 4.53 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-1 can be used for the research of cancer .
    Bcl-2/Mcl-1-IN-1
  • HY-144431

    Bcl-2 Family Cancer
    Bcl-2/Mcl-1-IN-3 (compound 1) is a Bcl-2/Mcl-1 inhibitor, with Kis of 0.14 μM and 0.23 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-3 can be used for the research of cancer .
    Bcl-2/Mcl-1-IN-3
  • HY-129681

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-2 (Compound Nap-1) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor with IC50s of 4.45 and 3.18 μM, respectively .
    MCL-1/BCL-2-IN-1
  • HY-129179
    Lisaftoclax
    1 Publications Verification

    APG-2575; Bcl-2/Bcl-xl inhibitor 1

    Bcl-2 Family Cancer
    Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively .
    Lisaftoclax
  • HY-P990344

    Bcl-2 Family Inflammation/Immunology
    The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Bcl-2 Antibody
  • HY-159513

    Bcl-2 Family Apoptosis Cancer
    Bcl-2/Mcl-1-IN-4 (compound 20) is a dual inhibitor targeting Bcl-2 (Ki=0.49 μM) and Mcl-1 (Ki=0.51 μM). Bcl-2/Mcl-1-IN-4 significantly inhibits cancer cell proliferation and effectively induces apoptosis in U937 cells. Bcl-2/Mcl-1-IN-4 can be used in cancer research .
    Bcl-2/Mcl-1-IN-4
  • HY-161415

    Ligands for E3 Ligase Cancer
    BCL-xL/BCL-2 ligand 1 (compound 72-1) is a BCL-xL and BCL-2 protein ligand. BCL-xL/BCL-2 ligand 1 can be connected to the E3 ligase by a linker to form PROTACs (HY-161410) [2].
    BCL-xL/BCL-2 ligand 1
  • HY-161786

    Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) Cancer
    Bcl-2-IN-20 (Compound 81) is an inhibitor for Bcl-2 with IC50 <10 μM (79.1% inhibition at 9 μM). Bcl-2-IN-20 exhibits cytotoxicity in SK-MEL-28 (IC50>10 μM), A549 (IC50=6.1 μM), HepG2 (IC50>10 μM), MCF-7 (IC50=8.9 μM), HCT116 (IC50>10 μM) and HEK-293 (IC50=14.1 μM). Bcl-2-IN-20 promotes the ROS production, induces apoptosis and DNA damage .
    Bcl-2-IN-20
  • HY-118874

    Bcl-2 Family Apoptosis Cancer
    Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research [2] .
    Oblimersen
  • HY-118874A

    Apoptosis Bcl-2 Family Cancer
    Oblimersen sodium is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen sodium specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen sodium can be used for cancer research [2] .
    Oblimersen sodium
  • HY-10087
    Navitoclax
    125+ Cited Publications

    ABT-263

    Bcl-2 Family Cancer
    Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax
  • HY-10087A1

    ABT-263 dihydrochloride

    Bcl-2 Family Cancer
    Navitoclax (ABT-263) dihydrochloride is an orally active Bcl-2 inhibitor that binds to various Bcl-2 family proteins, including Bcl-xL, Bcl-2, and Bcl-w, with a Ki value of less than 1 nM. Navitoclax dihydrochloride can be used in cancer research .
    Navitoclax dihydrochloride
  • HY-161276

    Apoptosis Bcl-2 Family Cancer
    BFC1108 is a small molecule Bcl-2 functional converter. BFC1108 induces a conformational change in Bcl-2, resulting in the exposure of its BH3 domain both in vitro and in vivo. BFC1108 effectively induces apoptosis in Bcl-2 expressing cancers. .
    BFC1108
  • HY-12020
    TW-37
    4 Publications Verification

    Bcl-2 Family Cancer
    TW-37 is a potent Bcl-2 inhibitor with Ki values of 260, 290 and 1110 nM for Mcl-1, Bcl-2 and Bcl-xL, respectively.
    TW-37
  • HY-123244

    Bcl-2 Family Apoptosis Cancer
    YC137 is a potent Bcl-2 antagonist with Kis of 1.3 μM and >100 μM for Bcl-2 and Bcl-xL when assayed in Bis-Tris buffer, respectively. YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. YC137 selectively induces apoptosis of Bcl-2-dependent cells. YC137 has the potential for breast cancer research [2].
    YC137
  • HY-10087S
    Navitoclax-d8
    1 Publications Verification

    Bcl-2 Family Cancer
    Navitoclax-d8 is the deuterium labeled Navitoclax. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax-d8
  • HY-10087R

    ABT-263 (Standard)

    Reference Standards Bcl-2 Family Cancer
    Navitoclax (Standard) is the analytical standard of Navitoclax. This product is intended for research and analytical applications. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax (Standard)
  • HY-12011
    HA14-1
    2 Publications Verification

    Bcl-2 Family Cancer
    HA14-1 is a Bcl-2/Bcl-XL antagonist. HA14-1 binds the designated pocket on Bcl-2 with the IC50 of ≈9 μM in competing with the Bcl-2 binding of Flu-BakBH3, and inhibits its function.
    HA14-1
  • HY-156620

    LP-108

    Bcl-2 Family Cancer
    Lacutoclax is a Bcl-2 inhibitor with antineoplastic activity .
    Lacutoclax
  • HY-122047

    Autophagy Cancer
    SW063058 is an autophagy inducer that specifically disrupts the binding of Beclin 1 to Bcl-2 while leaving the interaction between Bcl-2 and pro-apoptotic members like Bax and BIM unaffected. By inhibiting the negative regulatory effects of Bcl-2 on Beclin 1, which is crucial for the initiation of autophagy, SW063058 promotes autophagic activity without triggering cytotoxicity, apoptosis, or other forms of cell death in vitro.
    SW063058

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: